OBJECTIVES: I. Establish the safety and efficacy of extended maintenance zinc therapy in
200 patients with Wilson disease.
II. Establish further the role of zinc in the prophylactic treatment of presymptomatic
patients by increasing the current cohort from 80 to at least 100 patients.
III. Establish further the role of zinc therapy in pregnant patients with Wilson disease.
IV. Establish further the role of zinc therapy in children with Wilson disease.
Patients receive copper regulation therapy with zinc acetate: an existing cohort on
maintenance therapy will be followed for long-term data collection; presymptomatic patients
are treated prophylactically; and pregnant patients are evaluated for fetal outcome. All
patients are evaluated for copper balance, clinical control, and toxicity.
PROTOCOL ENTRY CRITERIA: Wilson disease Presymptomatic, pregnant, and children 16 years or
younger patients eligible Patient age: Any age, including children